Verbatim response from ChatGPT
Short answer
- Which works better: On average, tirzepatide (Zepbound) produces greater weight loss in clinical trials than semaglutide (Wegovy).
- Which is easier to get online: It depends. Wegovy has been on the market longer and is commonly prescribed via telehealth programs, but insurance/supply limits can make access hard. Zepbound is newer (and tirzepatide is also available as Mounjaro for diabetes), and some online clinics are prescribing tirzepatide off‑label — so in practice availability can be similar and varies by provider and region.
Why (brief)
- Efficacy: In obesity trials, semaglutide 2.4 mg (Wegovy) typically produced average body‑weight reductions in the low‑to‑mid teens percent range at ~68–72 weeks. Tirzepatide (the active in Zepbound) produced larger average reductions in many trials (higher percent weight loss, dose dependent). That’s the main reason many clinicians view tirzepatide as “more effective” for weight loss.
- Side effects & safety: Both are injectable weekly drugs that commonly cause gastrointestinal effects (nausea, vomiting, diarrhea, constipation). Both have safety considerations that require medical review (history of pancreatitis, gallbladder disease, pregnancy, and warnings about thyroid C‑cell tumors from animal studies). If you have diabetes or take other glucose‑lowering drugs, tirzepatide can affect blood glucose and hypoglycemia risk more than semaglutide, so management differs.
- Real‑world access: Wegovy has been in high demand (sometimes limited supply) and often needs prior authorization for insurance coverage. Zepbound is newer and initial supplies/specialty pharmacy pathways can also be constrained. Some prescribers will use Mounjaro (the diabetes brand of tirzepatide) off‑label for weight loss; that can make tirzepatide more accessible in some places but has legal/ethical considerations.
Getting them online — practical options and tips
- Talk to your primary care doctor or an endocrinologist first — they can assess safety, labs, and long‑term follow up (recommended).
- Reputable telehealth services that commonly evaluate and prescribe GLP‑1 or GIP/GLP‑1 drugs include Hims & Hers, Ro (Roman), PlushCare, Carbon Health, and local health‑system telemedicine programs. These services require medical history, a telemedicine visit, and often labs; availability and which drug they’ll prescribe vary.
- Manufacturer/assistance programs: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer patient support and savings programs — ask your clinician or the manufacturer’s patient support line.
- Insurance and cost: Check coverage and prior authorization requirements early. Out‑of‑pocket cost can be high without coverage.
- Avoid: buying injectable medications from unverified online pharmacies without a prescription or medical follow‑up.
How to decide for you
- If maximum weight loss is the primary goal and you have no contraindications, tirzepatide (Zepbound) tends to show larger mean weight loss in trials.
- If you have specific safety concerns (personal or family thyroid cancer history, pancreatitis, pregnancy plans) or want a longer track record for obesity, semaglutide (Wegovy) may be preferred.
- Discuss other health conditions (diabetes, heart disease), medications, and follow‑up plans with a clinician.
If you want, I can:
- Help you draft questions to ask a clinician when seeking one online, or
- Look up patient‑support links and manufacturer contact pages for Wegovy and Zepbound. Which would you prefer?